Compare PRMB & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRMB | GKOS |
|---|---|---|
| Founded | 1955 | 1998 |
| Country | United States | United States |
| Employees | 12600 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 6.0B |
| IPO Year | N/A | 2015 |
| Metric | PRMB | GKOS |
|---|---|---|
| Price | $23.41 | $122.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $24.00 | ★ $126.92 |
| AVG Volume (30 Days) | ★ 3.9M | 779.2K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | $2.34 | $23.32 |
| Revenue Next Year | $3.56 | $27.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $14.36 | $73.16 |
| 52 Week High | $33.29 | $148.11 |
| Indicator | PRMB | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 64.32 | 40.86 |
| Support Level | $21.53 | $79.59 |
| Resistance Level | $24.94 | $123.09 |
| Average True Range (ATR) | 0.98 | 6.56 |
| MACD | 0.04 | -1.43 |
| Stochastic Oscillator | 83.58 | 5.60 |
Primo Brands Corp is a North American branded beverage company focused on healthy hydration. It delivers sustainably and domestically sourced diversified offerings across products, formats, channels, price points, and consumer occasions, distributed in every state and Canada. Primo Brands is in reusable packaging, helping to reduce waste through its reusable, multi-serve bottles and brand packaging portfolio, which includes recycled plastic, aluminum, and glass.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.